MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/1747493020950903

Медицинская библиотека · International journal of stroke : official journal of the International Stroke Society · 2020

Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions.

Chen Yicong, Li Jianle, Ou Zilin, Zhang Yusheng, Liang Zhijian, Deng Weisheng, Huang Weixian, Wu Zhengdong, Jiang Haihong, Liu Qinghua, Ouyang Fubing, Xing Shihui, Zeng Jinsheng

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND AND PURPOSE: Aspirin is the first recommended antiplatelet agent to prevention secondary stroke, but its safety and efficacy in stroke patients with glucose-6-phosphate dehydrogenase deficiency remain unclear. We sought to evaluate its safety and efficacy in ischemic stroke patients with and without glucose-6-phosphate dehydrogenase deficiency.

METHODS

Patients with ischemic stroke receiving aspirin (100 mg/day) for three months were recruited for a multicenter, prospective, cohort study. Blood glucose-6-phosphate dehydrogenase activity was examined after stroke. Safety outcomes including acute hemolysis, moderate-to-severe bleeding, and death (vascular, all-cause), and efficacy outcome indicated as stroke recurrence were evaluated at three months. Risk factors associated with moderate-to-severe bleeding and all-cause death were determined using multivariate or Cox regression analysis.

RESULTS

Among the included 1121 patients, 81 of 130 glucose-6-phosphate dehydrogenase deficient and 576 of 991 glucose-6-phosphate dehydrogenase normal patients received aspirin for three months. Acute hemolysis was observed in one of the glucose-6-phosphate dehydrogenase deficient and in none of the glucose-6-phosphate dehydrogenase normal patients (p = 0.876). The rates of moderate-to-severe bleeding were 2.5% and 0.3% (p = 0.045), and the percentages of all-cause death were 6.2% and 1.4% (p = 0.008) in the glucose-6-phosphate dehydrogenase deficient and glucose-6-phosphate dehydrogenase normal patients. Stroke recurrence rate was similar in the two groups (2.5% vs. 1.7%; p = 0.608). Glucose-6-phosphate dehydrogenase deficiency was significantly associated with increased risk of moderate-to-severe bleeding (adjust p = 0.048) and all-cause death during aspirin use (adjust p = 0.008).

CONCLUSIONS

Long-term low-dose aspirin therapy might relate to worse safety outcomes in patients with glucose-6-phosphate dehydrogenase deficiency and large clinical trials are needed to further confirm these findings.

Для цитирования: Chen Yicong, Li Jianle, Ou Zilin, Zhang Yusheng, Liang Zhijian, Deng Weisheng, Huang Weixian, Wu Zhengdong, Jiang Haihong, Liu Qinghua, Ouyang Fubing, Xing Shihui, Zeng Jinsheng. Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions.. International journal of stroke : official journal of the International Stroke Society. 2020. DOI: 10.1177/1747493020950903.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.